[Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer: the MA-17 study]

MeSH terms

• Aged
• Antineoplastic Agents, Hormonal / adverse effects
• Antineoplastic Agents, Hormonal / therapeutic use*
• Aromatase Inhibitors
• Breast Neoplasms / drug therapy*
• Breast Neoplasms / therapy
• Chemotherapy, Adjuvant*
• Clinical Trials, Phase III as Topic
• Disease-Free Survival
• Enzyme Inhibitors / adverse effects
• Enzyme Inhibitors / therapeutic use
• Estrogens*
• Female
• Fractures, Bone / epidemiology
• Fractures, Bone / etiology
• Humans
• Letrozole
• Middle Aged
• Multicenter Studies as Topic
• Neoplasm Proteins / antagonists & inhibitors
• Neoplasms, Hormone-Dependent / drug therapy*
• Neoplasms, Hormone-Dependent / therapy
• Nitriles / adverse effects
• Nitriles / therapeutic use*
• Osteoporosis, Postmenopausal / chemically induced
• Osteoporosis, Postmenopausal / complications
• Osteoporosis, Postmenopausal / prevention & control
• Progesterone*
• Quality of Life
• Randomized Controlled Trials as Topic
• Tamoxifen / therapeutic use*
• Triazoles / adverse effects
• Triazoles / therapeutic use*